In 1997, Diatide expanded its pipeline to include therapeutic applications for its peptide technology.
Several candidates are in preclinical development.
The company also licensed a non-peptide compound and is developing this as an alternative to narcotics for reducing bone pain associated with metastatic cancer. This family will consist of a targeted imaging drug that identifies a tumor, and a corresponding therapeutic product that targets the same tumor. As part of its line of therapeutics for cancer, Diatide is engaged in a program to develop targeted therapeutics, called Theratides that link Diatide's proprietary, targeting peptides with cytotoxic radioisotopes chosen to kill tumors. Diatide also has synthesized several hundred cancer-targeted peptides and recently signed an agreement with Cngstrom Pharmaceuticals to access more. The Company's mission is to develop pharmaceuticals that target a wide array of markers found on tumor cell types of many cancers.